2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, McKay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2023, 7: 501-508. PMID: 37914579, DOI: 10.1016/j.euo.2023.10.002.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaInternational mRCC Database ConsortiumCytoreductive nephrectomySystemic therapy initiationMetastatic kidney cancerRenal cell carcinomaCombination immunotherapyDeferred CNUpfront CNCN statusPrimary tumorOverall survivalTherapy initiationCell carcinomaInternational Metastatic Renal Cell Carcinoma Database ConsortiumAdvent of novel therapeutic agentsKidney cancerInitiation of systemic therapyDiagnosis of metastatic diseaseTreatment of choiceProportion of patientsCox proportional-hazards regressionCharacterization of patientsIO-based combinationsProportional-hazards regressionA0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, Mckay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. A0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). European Urology 2023, 83: s473-s474. DOI: 10.1016/s0302-2838(23)00375-5.Peer-Reviewed Original Research
2022
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Navani V, Ernst M, Wells J, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, Powles T, McKay R, Weickhardt A, Suarez C, Kapoor A, Lee J, Choueiri T, Heng D. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2022, 5: e2216379. PMID: 35687336, PMCID: PMC9187954, DOI: 10.1001/jamanetworkopen.2022.16379.Peer-Reviewed Original ResearchConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaIO combination therapyInternational Metastatic Renal Cell Carcinoma Database Consortium riskPresence of lung metastasesCombination therapyCytoreductive nephrectomyComplete responseStable diseasePartial responseOverall survivalLung metastasesProgressive diseaseImmuno-oncologyImaging responseDiagnosis of metastatic renal cell carcinomaVascular endothelial growth factor inhibitorsIncreased likelihood of responseMedian overall survivalResponse Evaluation CriteriaGrowth factor inhibitorsMulticenter international cohort studyRenal cell carcinomaLikelihood of responseInternational cohort studyPredictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counseling
2020
Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
Meza L, Chehrazi-Raffle A, Pal S. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. Current Opinion In Urology 2020, 30: 740-742. PMID: 32732626, DOI: 10.1097/mou.0000000000000809.Peer-Reviewed Original Research